Evidence map›Paper›PMID 32527017›Full record

ArticleCancers2020

Serum Type XIX Collagen is Significantly Elevated in Non-Small Cell Lung Cancer: A Preliminary Study on Biomarker Potential.

Jeppe Thorlacius-Ussing, Tina Manon-Jensen, Shu Sun, Diana J Leeming, Jannie M Sand, Morten Karsdal, Nicholas Willumsen

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors.International journal of molecular sciences · 2022
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jeppe Thorlacius-UssingBiomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.ORCID 0000-0002-3340-0786
Tina Manon-JensenBiomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.
Shu SunBiomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.
Diana J LeemingBiomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.
Jannie M SandBiomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.
Morten KarsdalBiomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.
Nicholas WillumsenBiomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.
Nordic Bioscience (Denmark) · DKUniversity of Copenhagen · DK

Funding

Danish Research Foundation -
6 · The paper itself

Abstract

Type XIX collagen is a poorly characterized collagen associated with the basement membrane. It is abnormally regulated during breast cancer progression and the NC1 (XIX) domain has anti-tumorigenic signaling properties. However, little is known about the biomarker potential of collagen XIX in cancer. In this study, we describe a competitive ELISA, named PRO-C19, targeting the C-terminus of collagen XIX using a monoclonal antibody. PRO-C19 was measured in serum of patients with a range of cancer types and was elevated in non-small cell lung cancer (NSCLC) (

Indexed as

ADbiomarkercancerCollagen XIXECMNSCLCSCCserum

Identifiers

PMID32527017
PMCPMC7352985
OpenAlexW3034409637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.